Dr Rebecca Kristeleit

Dr Rebecca Kristeleit

BSc, MBChB, PhD, FRCP, FRSB

Oncology

26 years of experience
12 years as a specialist

Overall Rating

Overall Experience

5

Bedside Manner

5

Explanation

5

Top feedback

“Very approachable and understanding. Always explains procedures in layman's terms. Mainly face to face appointments “
Read more

Subspecialties

  • Medical Oncology
  • Endometrial Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Fallopian Tube Cancer
  • Gynaecological Oncology
  • Vaginal Cancer
  • Vulval Cancer
Show more

Languages spoken

  • English
Show more

Registered with

  • General Medical Council: 4178152
Show more

    Consultation fees

    New appointment: £350

    Follow-up appointment: £200

    Practices worked at

    Private Care at Guy’s at London Bridge Hospital

    Guy's Cancer Centre, Great Maze Pond, London, United Kingdom, SE1 9RT
    226 reviews

    About

    Dr Rebecca Kristeleit specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy's and St Thomas' NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy's Clinical Research Facility. She currently leads a large portfolio of Phase I-III clinical studies including immunotherapy for gynaecological malignancies.

    Dr Kristeleit qualified in 1995 from the University of Manchester after initially completing a BSc in medical science at the University of St Andrews. As an undergraduate, she was awarded an ERASMUS Scholarship which allowed her to study in Switzerland before completing an elective at Massachusetts General Hospital, Harvard University. She specialised in medical oncology at the Royal Marsden Hospital and obtained a CRUK-funded clinical research fellowship at the Institute of Cancer Research, being awarded a PhD in the clinical pharmacology of HDAC inhibitors.  She completed a Senior Fellowship at the Royal Marsden Hospital's Drug Development Unit in 2009 where she gained experience in experimental therapeutics. She was appointed Clinical Senior Lecturer and Honorary Consultant Medical Oncologist at UCL in 2009 and subsequently Associate Professor in Experimental Therapeutics at UCL.

    Dr Kristeleit is a member of the Target Ovarian Cancer Scientific Advisory Board, the Oncology and Haematology Expert Advisory Group for the Commission on Human Medicines, and has been elected to the ESMO Faculty from 2021 to 2025. She has over 100 peer-reviewed publications and is often asked to speak at national and international conferences as well as advise pharmaceutical companies on their gynaecological cancer drug development.

    Dr Kristeleit has previously served as Chair of the BGCS Scientific Committee, the UK Oncology Forum Gynaecology Track, and the ASCO Gynaecological Cancer Scientific Committee.

    Procedures

    • Immunotherapy
    • Biological Therapy
    • Chemotherapy
    • Clinical Trials
    • Genetic Testing
    • Hormone Therapy
    • Targeted Therapy
    Read more

    Special interests

    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
    • Fallopian Tube Cancer
    • Germ Cell Ovarian Cancer
    • Gynaecological Cancers
    • Vaginal Cancer
    • Vulval Cancer
    Read more

    Education

    • BSc Medical Science, University of St Andrews - 1992
    • MBChB, University of Manchester - 1995
    • MRCP, Royal College of Physicians - 1999
    • PhD, University of London - 2009
    • FRCP, Royal College of Physicians - 2016
    • FRSB, Royal Society of Biology - 2018
    Read more

    Insurers

    Powered by Doctify
    Promoting trust & transparency in healthcare